PMID- 31696010
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231014
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 11
IP  - 9
DP  - 2019 Sep 10
TI  - A Rising Hope of an Artificial Heart: Left Ventricular Assisted Device - Outcome, 
      Convenience, and Quality of Life.
PG  - e5617
LID - 10.7759/cureus.5617 [doi]
LID - e5617
AB  - With the introduction of mechanical circulatory support, mainly continuous-flow 
      left ventricular assisted devices (CF-LVAD), prolonging survival in end-stage 
      heart failure patients can be seen in a new light. We also anticipate its use as 
      a definitive therapy to overcome the limited donor organ resources for cardiac 
      transplant. However, LVADs also have undesirable device-related complications and 
      questionable improvement in the quality of life. In this review, we searched 
      published articles using PubMed and Google Scholar to identify the complications 
      and outcome of post-LVAD patients from 2014 to 2019. The studies we used included 
      all study design types and a wide range of demographic variables focusing on age, 
      sex, choice of LVAD as a bridge to cardiac transplant, or definitive therapy. For 
      patients with New York Heart Association (NYHA) Class III B or IV or heart 
      failure with reduced ejection fraction (HFrEF) with maximal medication therapy, 
      there is a significant increase in mean ejection fraction from 4% to 6%. For 
      patients with drug-induced cardiac toxicity or other causes of cardiac toxicity, 
      with no significant risk factors, the ejection fraction increased to nearly 50% 
      within 10-25 days of LVAD usage. There is also a substantial improvement in the 
      quality of life in this literature review comparing to the pre-LVAD stage, as 
      long as complications are taken into account. Data is limited for making an 
      accurate judgment on the quality of life and functional capacity of LVADs. We 
      found that the use of LVADs is not fully cost-effective, but still less 
      financially burdening than a cardiac transplant. Although data from worldwide is 
      limited and restricted to studies having a range of one to two years of 
      follow-up, we conclude that LVADs are promising in improving cardiac function and 
      the best bridging therapy available for patients waiting on a transplant.
CI  - Copyright (c) 2019, Thiha et al.
FAU - Thiha, Suyeewin
AU  - Thiha S
AD  - Internal Medicine, California Institute of Behavioural Neurosciences and 
      Psychology, Fairfield, USA.
FAU - Zaidi, Abdul Rehman Z
AU  - Zaidi ARZ
AD  - Internal Medicine, King Fahad Medical City, Riyadh, SAU.
FAU - Robert, Chris A
AU  - Robert CA
AD  - Obstetrics & Gynecology, Sunrise Hospital, Pune, IND.
FAU - Abbas, Mohammed K
AU  - Abbas MK
AD  - Internal Medicine, California Instititute of Behavioral Neurosciences and 
      Psychology, Fairfield, USA.
FAU - Malik, Bilal Haider
AU  - Malik BH
AD  - Internal Medicine, California Institute of Behavioral Neurosciences and 
      Psychology, Fairfield, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190910
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC6820898
OTO - NOTNLM
OT  - cost-effectiveness
OT  - ejection fraction
OT  - heart failure
OT  - left ventricular assist device (lvad)
OT  - lvad
OT  - quality of life
COIS- The authors have declared that no competing interests exist.
EDAT- 2019/11/07 06:00
MHDA- 2019/11/07 06:01
PMCR- 2019/09/10
CRDT- 2019/11/08 06:00
PHST- 2019/11/08 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2019/11/07 06:01 [medline]
PHST- 2019/09/10 00:00 [pmc-release]
AID - 10.7759/cureus.5617 [doi]
PST - epublish
SO  - Cureus. 2019 Sep 10;11(9):e5617. doi: 10.7759/cureus.5617.